Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.

Company Overview and News

Adherium Announces Patient Program with Connecticut Children’s Medical Center to Explore Best Practices for Access to Better Asthma Care Nationally

2018-07-10 globenewswire
SAN MATEO, Calif., July 10, 2018 (GLOBE NEWSWIRE) -- Adherium (ASX:ADR), a leading digital health company that improves medication adherence and patient outcomes, today announced a patient program with Connecticut Children’s Medical Center to help patients with asthma manage their condition with Adherium’s technology, the Hailie™ solution.

Adherium’s Technology Used for Large Scale Electronic Data Capture in Landmark Mild-Asthma Trials

2018-05-18 globenewswire
SAN MATEO, Calif., May 18, 2018 (GLOBE NEWSWIRE) -- Adherium (ASX:ADR), a digital health company that improves medication adherence and patient outcomes, announced the extensive use of it’s Hailie™ (previously known as Smartinhaler™) technology in two landmark clinical trials investigating the treatment of mild asthma, which have just been published in the New England Journal of Medicine and will be presented this weekend at the American Thoracic Society’s 2018 Congress.

Adherium Launches the Hailie™ Global Brand to Connect People with Asthma and COPD to Better Care

2018-05-16 globenewswire
SAN MATEO, Calif., May 16, 2018 (GLOBE NEWSWIRE) -- Adherium (ASX:ADR), an award-winning digital health company that improves medication adherence, patient outcomes and engagement, today announced the launch of the Hailie™ global brand to connect people with asthma and COPD to better care. The launch is a rebrand of the existing Smartinhaler™ brand, and includes the free Hailie™ app, an asthma and COPD tracking solution available on both iOS and Android, ultimately setting the stage for availability of Hailie™ sensors to consumers in the U.

Adherium Announces Program with Vitalus Health on World Asthma Day

2018-05-01 globenewswire
SAN MATEO, Calif., May 01, 2018 (GLOBE NEWSWIRE) -- In conjunction with World Asthma Day, Adherium (ASX:ADR), a digital health company that improves medication adherence and patient outcomes, announced today it has agreed to launch a program with Vitalus Health, targeting patients with chronic obstructive pulmonary disease (COPD) using the Adherium Smartinhaler technology. Vitalus Health is a leading provider of comprehensive health and wellness solutions that focus on pulmonary disease management throughout the southwest region of the United States.

Adherium Receives U.S. 510(k) Clearance for Over-the-Counter Sales of its Smartinhaler™ Sensor

2018-03-27 globenewswire
SAN MATEO, Calif., March 27, 2018 (GLOBE NEWSWIRE) -- Adherium (ASX:ADR), a digital health company that improves medication adherence and patient outcomes, today announced the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for over-the-counter (OTC) sales of its SmartinhalerTM sensor for AstraZeneca’s Symbicort® aerosol asthma inhaler.

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to ASX:ADR / ADHERIUM LIMITED on message board site Silicon Investor.

Madrigal Pharmaceuticals SNE - Sony Corp - ADR
seadrill SDRL Vimpel Comm (VIP) ADRu0027s of the Russian Cellular Phone Co.
Cadre Resources (CSL.V) Awaiting production #u0027s and Financ Telefonica S.A. (ADR)
Sanofi-Aventis (ADR: SNY) ABB (Asea Brown Boveri) ADR
Allen-Vanguard Corp (TSE: VRS, ADR: ALNVF) THE San Diego Padres and Chargers board